HL Science Q1 2026: Revenue down 58% YoY, net loss narrows

Consolidated revenue of KRW 2.13B, down 58% YoY from KRW 5.08B
Operating loss of KRW 2.25B, narrowing from KRW 2.96B in the same period last year
Net loss of KRW 1.88B, improving from KRW 2.47B YoY
Debt ratio of 2.81% (vs 2.75% at year-end), very low
Cash and cash equivalents + other liquid financial assets of KRW 24.9B, stable financial position
R&D expenses of KRW 289M (13.5% of revenue), continued investment
No dividends or share buyback/cancellation
Key pipelines (natural drug, individual recognition raw materials) in progress but monetization delayed